HC Wainwright & Co. maintains Buy rating on Dyne Therapeutics, $32 price target
HC Wainwright & Co. maintained their Buy rating on Dyne Therapeutics's stock with a price target of $32.00.The price target implies an upside of 97.4% from the Sep 29 close of $16.21.Key takeaways from the analyst noteStrong Pipeline Potential: Dyne Therapeutics is actively developing a promising p…